Stem Cells and Tibial Fractures

Not Applicable

Withdrawn

• Conditions: Tibial Fractures
• Interventions: Other: CD34+ haemopoietic stem cells

• Registration Number: NCT00632034
• Lead Sponsor: Imperial College London

Brief Summary

The aim of this trial is to determine the safety and tolerability of expanded autologous progeny of an adult CD34+ (haemopoietic) stem cell subset when infused directly into the tibial artery of patients with recent tibial fracture. The trial will also seek to determine clinical improvement or deterioration by measurement of clinical parameters such as, length of time to union of the fracture, changes in bone mineral density, improvements in pain scores (VAS), functional ability (TUGT) and IPAQ scores.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2008-02-29
• Study First Submitted QC: 2008-02-29
• Study First Posted: 2008-03-10
• Study Start: 2010-05
• Primary Completion: 2012-07
• Study Completion: 2012-07
• Status Verified: 2019-07
• Last Update Submitted: 2019-07-11
• Last Update Posted: 2019-07-15

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Confirmed closed tibial fracture on one limb only
• Normal blood count
• Normal coagulation screen
• Life expectancy of at least 12 months
• Ability to give written informed consent

Exclusion Criteria

• Patients with additional lower limb injuries
• Patients with abnormal lower limb vasculature
• Pregnant or lactating women
• Unexplained abnormal baseline laboratory results
• Males and females who are capable of reproduction and will not take acceptable measures to prevent reproduction during the study
• Subjects who test positive for HTLV, HIV, hepatitis B or hepatitis C, have a chronic inflammatory disease, autoimmune disease or are on chronic immunosuppressive medications
• History of alcohol or drug abuse within 3 months of screening
• Subjects with evidence (clinical, laboratory, or imaging) of cancer or cancer recurrence within the past 5 years (other than non-melanoma skin cancer or in situ cervical carcinoma)
• Currently enrolled in another investigational device or drug trial that has not completed the required follow-up period
• Patients unable to give written informed consent

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
1	CD34+ haemopoietic stem cells	-

Primary Outcome Measures

Name	Time	Method
To assess the safety of expanded autologous progeny of an adult CD34+ stem cell subset when introduced into the tibial artery and to determine absence of adverse events at the maximum dose of cells of 1,000,000,000 cells in a dose escalation regime.	1 year

Secondary Outcome Measures

Name	Time	Method
To assess improvement in bony union as measured by imaging modalities and determine whether there are any significant improvements in early restoration of function as reported by the patients.	1 year

Trial Locations

Locations (1)

Charing Cross Hospital; 🇬🇧 London, United Kingdom